The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of factors to predict low risk febrile neutropenia admissions in patients with acute myeloid leukemia (AML) following intensive chemotherapy.
 
Khushboo Pal
No Relationships to Disclose
 
Zahra Ali
No Relationships to Disclose
 
Megan Othus
Consulting or Advisory Role - Biosight; Cascadia Labs; Daiichi Sankyo; Glycomimetics; Merck
Other Relationship - Celgene; Glycomimetics
 
Katie Russell
No Relationships to Disclose
 
Carole Shaw
No Relationships to Disclose
 
Mary-Elizabeth M. Percival
No Relationships to Disclose
 
Paul Hendrie
No Relationships to Disclose
 
Roland B. Walter
Stock and Other Ownership Interests - Amphivena Therapeutics
Consulting or Advisory Role - Abbvie; Adicet Bio; BerGenBio; BiolineRx; Bristol-Myers Squibb/Celgene/Juno; Genentech; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Kronos; Kura Oncology; Orum Therapeutics; Pfizer; Stemline Therapeutics
Research Funding - Amgen (Inst); Aptevo Therapeutics; Arog (Inst); Celgene; Immunogen (Inst); Janssen Research & Development (Inst); Jazz Pharmaceuticals (Inst); Kite/Gilead; Kura Oncology; Macrogenics (Inst); Pfizer; Selvita (Inst)
 
Anna B. Halpern
Consulting or Advisory Role - Abbvie; Agios; Notable labs
Research Funding - Bayer (Inst); disc medicine (Inst); Gilead/Forty Seven (Inst); Imago Pharma (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst)